Liver Carcinoma

27 registered clinical trials studyying Liver Carcinoma — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and NCT06717295	Javier Toledo	—
Enrolling By Invitation	Clinical Evaluation of an Augmented Reality Intraprocedural Needle Guidance Platform for Soft Tissue Biopsy NCT07046832	MediView XR, Inc.	N/A
Recruiting	The Vanguard Study: Testing a New Way to Screen for Cancer NCT06995898	National Cancer Institute (NCI)	N/A
Active Not Recruiting	Radiofrequency-responsive Layered Double Hydroxides for Enhanced Arterial Embolization and Thermal Immunothera NCT06966986	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	—
Completed	Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma NCT05681234	Affiliated Hospital of Jiangnan University	N/A
Completed	Ex-vivo Hypotermic Perfusion in Patients With Hepatocellular Carcinoma to Reduce the Incidence of Tumor Recurr NCT06720675	IRCCS Azienda Ospedaliero-Universitaria di Bologna	—
Unknown	Liver Transplantation for Unresectable GIST Liver Metastases NCT04825470	Hospital Universitario Virgen de la Arrixaca	N/A
Unknown	A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the T NCT06144385	Shanghai Ming Ju Biotechnology Co., Ltd.	Phase 1
Completed	Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Usin NCT06789224	Lindis Bloodcare GmbH	N/A
Unknown	Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers NCT04682847	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	—
Unknown	Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dule NCT04443322	RenJi Hospital	N/A
Completed	Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) NCT04288323	University of California, San Diego	Phase 4
Completed	AFP Model and Liver Transplantation. NCT03775863	Austral University, Argentina	—
Suspended	Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or NCT04955808	National Cancer Institute (NCI)	—
Active Not Recruiting	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph NCT02465060	National Cancer Institute (NCI)	Phase 2
Completed	Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation NCT02424955	Stanford University	N/A
Completed	CIRSE Registry for SIR-Spheres Therapy NCT02305459	Cardiovascular and Interventional Radiological Society of Europe	—
Withdrawn	Analysis of Body Composition in Patients With Hepatocellular Carcinoma in Radioablation NCT01744639	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	N/A
Completed	SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma NCT01482442	Assistance Publique - Hôpitaux de Paris	Phase 3
Unknown	The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma NCT01380392	National Taiwan University Hospital	—
Unknown	Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Ra NCT01272557	PD Dr. med. Matthias Dollinger	Phase 2
Terminated	Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma NCT01020812	Stanford University	Phase 1 / Phase 2
Terminated	Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma NCT00791544	Sanofi	Phase 1 / Phase 2
Terminated	Permission to Collect Blood Over Time for Research NCT00767234	Stanford University	—
Completed	Combined HCC-MFCCC NCT03178409	University of Milan	—
Completed	Hepatocellular Carcinoma Treated With Iodine-125 Implantation NCT01717729	The Second People's Hospital of GuangDong Province	Phase 3
Completed	De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma NCT00328770	University of Alberta	Phase 2 / Phase 3